ArticleClinical ophthalmology (Auckland, N.Z.)2026
Visual Recovery with Cryopreserved Amniotic Membrane After Epi-Off Corneal Cross-Linking in Keratoconus Patients: A Non-Randomized, Controlled, Retrospective Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study assessed whether application of cryopreserved amniotic membrane (AM) improves recovery after collagen cross-linking (CXL) using the Dresden protocol in patients with progressive keratoconus. Methods: This single-centre, retrospective, non-randomized, comparative study included consecutive patients with progressive keratoconus who underwent epi-off CXL followed by bandage contact lens (BCL) or cryopreserved AM (Prokera Slim). Patients were assessed preoperatively and at 1 week, 1 month, 3 months, and 6 months postoperatively. Outcomes included best-corrected visual acuity (BCVA), maximum keratometry (K Results: A total of 62 eyes (46 patients) were treated with AM after CXL, and 46 eyes (39 patients) received BCL. At 6 months post-op, a significantly greater proportion of eyes in the AM group returned to baseline BCVA versus the BCL group (85.7% vs 64.9%, p < 0.05). BCVA logMAR was significantly better in the AM treatment group compared to the BCL group at 6-months (0.19 ± 0.21 vs 0.31 ± 0.28, respectively; p=0.046). The change in K Conclusion: The use of AM after epi-off CXL resulted in no post-operative complications and improved BCVA six months after surgery compared to a BCL. Prospective, randomized controlled studies are warranted to verify these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.